BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

Accurate quantification of minimal residual disease (MRD) during treatment of chronic myeloid leukemia (CML) guides clinical decisions. The conventional MRD method, RQ-PCR for BCR-ABL1 mRNA, reflects a composite of the number of circulating leukemic cells and the BCR-ABL1 transcripts per cell. BCR-A...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Haematologica
Auteurs principaux: Pagani, Ilaria S., Dang, Phuong, Kommers, Ivar O., Goyne, Jarrad M., Nicola, Mario, Saunders, Verity A., Braley, Jodi, White, Deborah L., Yeung, David T., Branford, Susan, Hughes, Timothy P., Ross, David M.
Format: Artigo
Langue:Inglês
Publié: Ferrata Storti Foundation 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6269287/
https://ncbi.nlm.nih.gov/pubmed/29976745
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.189787
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires